Summary
| Direction in PACVS | ↑ Elevated — higher than in the comparison group |
|---|---|
| Category | Autoimmune |
| Also described as | 16 autoantibodies tested |
| Compared against | HC (healthy controls) |
| Associated symptoms | Dysautonomia, vascular instability |
| Test type | Blood test (serum / plasma / whole blood) |
| Source | Mantovani et al. 2024 — doi:10.3390/biomedicines12122852 |
| Condition atlas | PACVS Biomarker Atlas |
Other conditions where Anti-GPCR autoantibodies (panel) is reported
- Anti-GPCR autoantibodies in Long COVID — ↑ elevated vs HC
- Anti-GPCR autoantibodies (panel) in ME/CFS — ↑ elevated vs HC — LC/PACVS overlap
See the cross-condition hub: Anti-GPCR autoantibodies (panel) across conditions.
Trials, interventions and tests
Commercial test availability
GPCR Functional Autoantibody Panel — specialty laboratory test. Functional autoantibody testing; not standard hospital lab menu.
Links are for reference only; availability, specimen requirements and coverage vary by location.
Related Autoimmune markers in PACVS
- Anti-idiotype antibodies (ACE2 ↔ Anti-S) ↕
- Anti-CHRM3 (muscarinic M3) ↕
- Anti-ADRA2A (α2B adrenergic receptor) ↓
- Anti-STAB1 autoantibodies ↑
- Anti-MAS1 receptor autoantibodies ↑
- Anti-AT1R (angiotensin II type 1 receptor) ↑
- Anti-ACE2 autoantibodies ↑
Full list: PACVS Biomarker Atlas.
Frequently asked questions
Is Anti-GPCR autoantibodies (panel) high or low in PACVS?
Elevated. Studies summarised in the OSMF atlas report higher Anti-GPCR autoantibodies (panel) in PACVS than in healthy controls. Source: Mantovani et al. 2024.
What symptoms is Anti-GPCR autoantibodies (panel) associated with in PACVS?
The cited literature associates this marker with Dysautonomia, vascular instability. These are population-level associations and do not mean the marker causes the symptoms.
Which test measures Anti-GPCR autoantibodies (panel)?
It is measured as a blood test (serum / plasma / whole blood). Commercial laboratories such as CellTrend (specialty) list an orderable assay.
Is one abnormal Anti-GPCR autoantibodies (panel) result diagnostic of PACVS?
No. No single biomarker is diagnostic of PACVS. Anti-GPCR autoantibodies (panel) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Is Anti-GPCR autoantibodies (panel) specific to PACVS?
No. The same marker is also reported in Long COVID, ME/CFS in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-30 · Page generated from pacvs.json · Browse: PACVS atlas · Biomarker Index · All marker pages
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.